Cancer Therapy Related News
Defence Therapeutics announces successful ARM-002TM cancer vaccine results
Defence Therapeutics has announced the successful testing of its second-generation anti-cancer vaccine, named ARM-002TM, utilising its flagship anti-cancer molecule, AccuTOX®.
The ARM-002TM cancer vaccine, when...
New endometrial cancer immunotherapy approved by the NHS
The NHS is set to introduce an immunotherapy that could potentially provide significant additional time for women battling endometrial cancer.
Defence Therapeutics granted US patent for AccuTOX® technology
Defence Therapeutics has achieved a significant milestone with the granting of US patent no. 11,890,350 ('350) by the United States Patent and Trademark Office...
Anti-diabetic drugs may lower brain cancer risk, says the University of Bristol
Researchers from the University of Bristol have uncovered a potential link between long-term use of certain anti-diabetic drugs and a reduced risk of primary...
Tohoku University develops monoclonal antibody for HER2-positive breast cancer
Tohoku University have engineered a groundbreaking monoclonal antibody aimed at HER2-positive breast cancer.
Defence Therapeutics granted FDA approval for Phase I Clinical Trial of AccuTOX®
Defence Therapeutics has announced a pivotal milestone: the U.S. Food and Drug Administration (FDA) has granted a green light with a "Study May Proceed"...
Defence Therapeutics applies to use AccuTOX® as an advanced tumour treatment
Defence Therapeutics has submitted an Investigational New Drug application for AccuTOX®, an injectable anticancer molecule.
Defence Therapeutics awarded CIPO patent for vaccine technology
Defence Therapeutics has announced that the Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance for the company's Canadian patent application no....
AccuTOX® anticancer drug demonstrates exciting antigen cross-presentation
Defence Therapeutics Inc., a prominent Canadian biopharmaceutical company renowned for its work in immune-oncology vaccines and drug delivery technologies, has announced the discovery of...
Accum®-mRNA lipid nanoparticles have double the antibody response of traditional mRNA vaccines
Defence Therapeutics has announced a groundbreaking achievement, demonstrating that its Accum®-mRNA lipid nanoparticles elicit twice the antibody response of mRNA-based vaccines.
The company's encapsulation strategy,...
Researchers discover new target to combat cancer drug resistance
In a groundbreaking development, scientists at the University of Queensland have pinpointed a novel drug target with immense promise in combating cancer drug resistance...
How Defence’s Accum® technology is advancing cancer therapeutics
Industry-leading biotechnology pioneer Defence Therapeutics details how the company is advancing immune oncology through its revolutionary Accum® technology.
Whether using an antibody, cell-based vaccine or...
UK and BioNTech SE sign landmark deal for cancer vaccine trials
The UK Government has established a historic agreement with German-based BioNTech SE for cancer vaccine trials.
The groundbreaking deal will improve access to cancer vaccine...
Defence work with City of Hope in filing a new AccuTOX cancer programme
Defence Therapeutics has teamed up with City of Hope to submit an application for the clinical trialling of their AccuTOX TM technology.
The Canadian biopharmaceutical...
Defence Therapeutics has US patent accepted for Accum
Defence Therapeutics Inc, a Canadian biopharmaceuticals company primarily focussed on the development of novel immune-oncology vaccines and drug delivery technologies including Antibody Drug Conjugate...
A new biomarker can measure CAR-T cell therapy response
Researchers have discovered a potent biomarker for clinical responses to CAR-T cell therapy that could improve lymphoma treatment.
The findings from MedUni Vienna could provide...
Lung cancer immunotherapy side effects prevented with genetic discovery
Scientists at Edith Cowan University have made a groundbreaking genetic discovery that may eliminate side effects from lung cancer immunotherapy.
Of all types of cancer, lung...
Alpelisib becomes 100th fast tracked NHS cancer drug
Alpelisib – a life-extending drug for patients with advanced breast cancer – has become the 100th fast-tracked cancer drug on the NHS and will...
Drug treatment for uveal melanoma shows exciting results
Effective drug treatment for a rare type of eye cancer known as uveal melanoma (UM) may soon be on the horizon, thanks to a...
Scientists identify a range of new bladder cancer treatments
A study performed at MedUni Vienna has discovered hundreds of new potential bladder cancer treatments, with one commonly used drug demonstrating effectiveness against two...
